Skip to main content

Publication, Part of

National Diabetes Audit, 2019-20 , Type 1 Diabetes

Audit, Survey, Other reports and statistics, Official statistics

Summary

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020.

This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.


Key Facts

•The number of people with type 1 diabetes confirmed at an adult specialist service was low (78,585, 35.9 per cent of the total number of people with type 1 diabetes, 218,670). From 135 acute hospital trusts, some with multiple hospitals: 38 submitted the core and insulin pump datasets; 5 submitted only the pump dataset; 55 submitted only the core dataset. This is a much lower level of participation than for the National Paediatric Diabetes Audit*.
•The national median rate for HbA1c ≤ 58mmol/mol (7.5%) is 27.6 per cent, with a variation between 18.4 per cent and 40.9 per cent amongst Clinical Commissioning Groups (CCGs)/Local Health Boards (LHBs).
•Individuals with type 1 diabetes are more likely to have recommended HbA1c levels if they are on insulin pump treatment. Overall, around 10 per cent of people with type 1 diabetes use insulin pumps, but this varies appreciably by CCG/LHB locality from 3.2 per cent to 24.6 per cent. More than 70,000 people with type 1 diabetes meet one of the NICE criteria for offering insulin pump treatment as they are on basal-bolus treatment and have an HbA1c ≥ 69 (8.5%).
•Individuals with type 1 diabetes are more likely to have high HbA1c levels (>86mmol/mol) if they are young, female, of minority ethnicity, or live in an area of high deprivation.


Last edited: 10 August 2021 3:55 pm